Metabolic Effect of Combined Telmisartan and Nifedipine CR Therapy in Patients with Essential Hypertension

Metabolic Effect of Combined Telmisartan and Nifedipine CR Therapy in Patients with Essential Hypertension - Metabolic Effect of Combined Telmisartan and Nifedipine CR Therapy in Patients with Essential Hypertension

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000007720

Enrollment

Registered

2012-04-10

Start date

2005-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Hypertension without metabolic disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatients with essential hypertension whose office systolic BP (SBP) was greater than 140 mmHg or whose diastolic BP (DBP) was greater than 90 mmHg on more than 2 different occasions. All patients were received telmisartan(40mg/day) for 6 weeks. Patients whose office BP did not reduced to 140/90 mmHg after 6 weeks took nifedipine CR (20-40mg/day) for 18 weeks. Other patients received only telmisartan for 18 weeks.

Exclusion criteria

Exclusion criteria: Patients had diabetes mellitus, hypercholesterolemia, metabolic syndrome or cardiovascular disease and were not taking any anti-hypertensive medicines for at least 6 months.

Design outcomes

Primary

Measure	Time frame
Metabolic parameters (lipids, glucose, Homa-IR, leptin and aoponectin)	—

Secondary

Measure	Time frame
Blood pressure, heart rate, body weight, and Blood chemistry analysis, neurohormonal parameters (noradrenaline, plasma renin activity, aldosterone)	—

Countries

Japan

Contacts

Public ContactFumiyasu Yamasaki

Kochi Medical School Clinical Laboratory

yamasakf-kochimed@umin.net088-866-5811

Outcome results